Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANA
NCT06640283Phase 2
Key facts
- Status
- Recruiting
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Countries
- 1
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Drugs
- pembrolizumab
- Conditions
- Cervical Cancer (CC)anal canal cancer
01
Overview
Phase 2, open-label trial of pembrolizumab in Cervical Cancer (CC) and anal canal cancer (2 arms), sponsored by Instituto do Câncer do Estado de São Paulo. Primary endpoint: General Objective at 2 years. Started Mar 2025; status: recruiting.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
Active laboratory monitoring
Phase I Monitoring through collection of laboratory tests
Intervention with Immunotherapy
Phase II for participants who are ctDNA positive after standard treatment. Intervention will be with Pembrolizumab
03
Who it enrols
Adult patients with HPV-related, locally confined or locally advanced anal canal or cervical cancer indicated for definitive radiotherapy.
04
Endpoints
Primary
General Objective
Beyond the preview
Go deeper on NCT06640283.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640283.